In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model

• Váldodahkkit: Iwan P. Williams (Dahkki), Silvia Crescioli (Dahkki), Heng Sheng Sow (Dahkki), Heather J. Bax (Dahkki), Carl Hobbs (Dahkki), Kristina M. Ilieva (Dahkki), Elise French (Dahkki), Giulia Pellizzari (Dahkki), Vivienne Cox (Dahkki), Debra H. Josephs (Dahkki), James F. Spicer (Dahkki), Sophia N. Karagiannis (Dahkki), Silvia Mele (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

IgE monoclonal antibodies hold great potential for cancer therapy. Preclinical in vivo systems, particularly those in which the antibody recognizes the host species target antigen and binds to cognate Fc receptors, are often the closest approximation to human exposure and represent a key challenge f...